GOSS vs UTHR

Gossamer Bio (GOSS) remains a high-risk, high-reward biotech opportunity, primarily driven by its lead asset, GB004 (seralutinib), for Pulmonary Arterial Hypertension (PAH). The significant positive Phase 2 TORREY study results, announced in late 2024, substantially de-risked the asset, validating its potential as a first-in-class, oral treatment in a market with high unmet needs. This solidifies ...

United Therapeutics possesses a robust core business in rare disease therapeutics (PAH), generating substantial cash flow that prudently funds its ambitious and visionary xenotransplantation program. While the long-term potential of organ manufacturing is immense, addressing a colossal unmet medical need and positioning for future market leadership, the path to commercialization involves monumenta...